Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Tax Provisions (2022 - 2025)

Historic Tax Provisions for Sunshine Biopharma (SBFM) over the last 4 years, with Q3 2025 value amounting to -$137438.0.

  • Sunshine Biopharma's Tax Provisions fell 16386.02% to -$137438.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$515502.0, marking a year-over-year decrease of 55161.64%. This contributed to the annual value of -$234858.0 for FY2024, which is 15943.27% down from last year.
  • Latest data reveals that Sunshine Biopharma reported Tax Provisions of -$137438.0 as of Q3 2025, which was down 16386.02% from -$209166.0 recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Tax Provisions peaked at $233304.0 during Q4 2022, and registered a low of -$343691.0 during Q2 2024.
  • Moreover, its 4-year median value for Tax Provisions was $31652.5 (2023), whereas its average is $570.58.
  • The largest annual percentage gain for Sunshine Biopharma's Tax Provisions in the last 5 years was 42553.48% (2024), contrasted with its biggest fall of 49199.68% (2024).
  • Sunshine Biopharma's Tax Provisions (Quarter) stood at $233304.0 in 2022, then decreased by 5.59% to $220267.0 in 2023, then plummeted by 158.45% to -$128737.0 in 2024, then decreased by 6.76% to -$137438.0 in 2025.
  • Its Tax Provisions was -$137438.0 in Q3 2025, compared to -$209166.0 in Q2 2025 and -$40161.0 in Q1 2025.